1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hyundai Pharmaceutical Co., Ltd.

Hyundai Pharmaceutical Co., Ltd.

KKRX:004310
6,790.00
KRW
-200.00
(-2.86%)
208.38BMarket Cap
Hyundai Pharmaceutical Co., Ltd.
KRX:004310
(Korea Stock Exchange)

Recent

price

6,790.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
4,552.36
4,673.92
4,251.37
4,492.11
4,507.31
4,564.68
4,771.11
5,362.1
4,719.12
4,884.85
4,863.71
5,022.57
5,930.98
6,673.3
6,725.11
7,338.24
- -
Revenue per Share
120.79
40.91
-201.64
58.78
61.37
66.24
55.52
-69
-76
44
80
-114
-6
226
-22
96.28
- -
Basic EPS, GAAP
-79.15
168.23
-199.88
236.25
92.88
-221.67
-255.49
-213.68
6.07
121.7
161.08
-60.24
183.73
-393.16
-518.8
-229.11
- -
Free Cash Flow per Basic Share
49.82
43.65
39.02
36.63
41.66
43.88
46.04
48.15
42.56
44.7
44.43
42.55
30.48
30.5
35.33
29.99
- -
Dividend per Share
3,842.79
3,820.45
4,121.95
4,183.45
4,348.83
4,173.47
3,949.36
3,487.86
3,218.5
3,090.94
3,233.36
3,106.36
3,143.63
3,174.38
3,025.52
2,655.66
4,141.78
Book Value per Share
3,827.05
3,804.82
4,021.78
4,107.48
4,274.29
4,103.56
3,819.93
3,265.26
2,943.36
2,792.36
2,783.51
2,623.3
2,515.25
2,963.19
2,768.49
2,419.26
3,848.42
Tangible Book Value per Share
25
24
24
24
24
24
25
24
28
28
27
28
27
27
26
26
27
Basic Weighted Avg Shares
111,860
113,046
102,253
108,135
107,837
109,829
120,022
127,584
130,791
134,650
132,966
139,803
162,690
180,763
175,735
191,790
- -
Sales/Revenue/Turnover
0.97
3.32
-4.22
2.02
2.09
1.55
2.05
-0.96
-2.03
1.52
2.3
-1.12
4.9
3.83
0.1
2.17
- -
Operating Margin (%)
2,289
2,274
2,357
2,111
1,909
1,964
2,238
2,754
3,200
3,513
4,112
3,979
3,297
3,300
3,688
4,279
- -
Depreciation Expense
2,968
990
-4,850
1,415
1,468
1,594
1,397
-1,642
-2,106
1,213
2,187
-3,173
-165
6,122
-575
2,516
- -
Net Income, GAAP
21.77
58.02
- -
- -
8.7
68.33
5.84
- -
- -
20.37
18.48
- -
102.9
23.8
- -
- -
- -
Effective Tax Rate (%)
2.65
0.88
-4.74
1.31
1.36
1.45
1.16
-1.29
-1.61
0.9
1.64
-2.27
-0.1
3.39
-0.33
1.31
- -
Profit Margin (%)
42,463
41,130
42,354
43,833
43,331
38,881
35,579
16,827
19,887
21,364
28,724
39,045
20,947
20,139
20,875
9,417
44,357
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
206
15,324
10,090
581
14,798
5,792
26,831
LT Debt
92,505
91,967
99,687
101,212
104,687
104,432
97,763
82,255
88,126
83,424
90,141
86,600
86,555
84,661
79,074
82,103
128,049
Total Equity
0.74
1.38
- -
- -
1.67
0.43
1.85
- -
- -
1.54
2.29
- -
-0.19
4.23
- -
- -
- -
Return on Invested Capital (%)
3.44
1.29
- -
- -
1.71
1.42
1.57
- -
- -
1.64
2.45
- -
-0.16
6.06
- -
- -
- -
Return on Capital (%)
3.21
1.07
-5.07
1.42
1.43
1.52
1.38
-1.82
-2.47
1.41
2.52
-3.59
-0.19
7.15
-0.7
3.12
- -
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Nov'25
Feb'26
May'26
ST Debt
44,138
44,593
23,081
LT Borrowings
5,660
5,428
26,677
LT Finance Leases
133
103
154
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
31
Market Capitalization
114,391
368,523
208,376

Working Capital

KRW

•

in mil. unless spec.
Nov'25
Feb'26
May'26
Total Current Assets
80,828
100,632
108,446
Cash, Cash Equivalents & STI
2,772
18,944
18,985
Accounts Receivable, Net
42,268
41,575
47,479
Inventories
32,595
38,494
37,666
Total Current Liabilities
71,411
78,896
64,089
Payables & Accruals
- -
- -
- -
ST Debt
44,138
44,593
23,081
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.13%
-1.79%
3.83%
Free Cash Flow
94.48%
-175.7%
-55.83%
Net Income, GAAP
-508.54%
-961.31%
-537.7%
Sales/Revenue/Turnover
5.88%
7.8%
9.14%
Total Cash Common Dividend
-2.18%
-7.29%
-15.1%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
42,772
43,881
46,221
42,862
175,735
2025
43,087
48,414
- -
48,723
191,790
2026
46,454
55,585
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12
52
-19
-56.57
-22
2025
-38
37
- -
10.26
96.28
2026
16.03
39
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
35.33
2025
- -
- -
- -
- -
29.99
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hyundai Pharmaceutical Co., Ltd. is a South Korea-based company primarily engaged in the development, manufacture, and distribution of pharmaceutical products, health food drinks, and medical devices. Founded in 1989 and headquartered in Seoul, the company offers a broad portfolio of core pharmaceutical products including ethical and over-the-counter (OTC) drugs across multiple therapeutic areas such as cardiovascular diseases, endocrine disorders (notably diabetes), central nervous system conditions (including depression, schizophrenia, Alzheimer’s, and Parkinson’s), pain management, women’s health, respiratory ailments, oncology, and dermatology. Key pharmaceutical product categories include antianginals, antibiotics, antiemetics, antihistamines, antihyperlipidemics, antihypertensives, antiplatelet agents, antitussives, and cell stimulants. In addition to pharmaceuticals, Hyundai Pharm markets health food beverages and medical devices domestically and explores diverse partnership opportunities such as licensing, co-marketing, co-promotion, and joint ventures with global pharmaceutical companies. Recent major developments include Hyundai Pharmaceutical’s exclusive licensing and commercialization agreement signed in 2023 with Cosmo Pharmaceuticals for the dermatology product Winlevi® (clascoterone) cream 1%, approved by South Korean regulatory authorities in 2025 for treating acne vulgaris. This strategic alliance leverages Cosmo’s global dermatology innovation and Hyundai Pharm’s local expertise to address unmet acne treatment needs in Korea. Moreover, Hyundai Pharm has patented novel USP1 inhibitors targeting cancer treatments, reflecting its expanding focus on oncology innovation. The company also maintains various exclusive distribution and licensing agreements for products like Kytril (antiemetic), Twyneo and Epsolay (acne and rosacea treatments), and Bijuva (menopausal hormone therapy), emphasizing its continued expansion into specialty pharmaceuticals and women's health markets. Hyundai Pharm’s operations focus predominantly on South Korea, with active collaborations and licensing agreements facilitating its product portfolio and pipeline diversification. Overall, Hyundai Pharmaceutical Co., Ltd. stands as an integrated pharmaceutical company with a comprehensive product lineup across major therapeutic areas, supplemented by strategic international partnerships and recent advancements in dermatology and oncology products, positioning it for sustained growth within the South Korean pharmaceutical industry.